COVID-19 vaccine antibody response is associated with side-effects, chronic health conditions, and vaccine type in a large Northern California cohort DOI Creative Commons
Olivia Solomon, Cameron Adams, Mary Horton

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Oct. 1, 2022

Abstract As vaccines have become available for COVID-19, it is important to understand factors that may impact response. The objective of this study describe vaccine response in a well-characterized Northern California cohort, including differences side-effects and antibody by type, sex, age, as well responses subjects with pre-existing health conditions are known risk more severe COVID-19 infection. From July 2020 March 2021, ∼5,500 adults from the East Bay Area were followed part longitudinal cohort study. Comprehensive questionnaire data biospecimens testing collected at multiple time-points. All least 18 years age members East-Bay who answered questionnaires related vaccination status two Three vaccines, Moderna (2 doses), Pfizer-BioNTech Johnson & (single dose), examined exposures. Additionally, assessed. main outcomes interest anti-SARS-CoV-2 Spike (measured S/C ratio Ortho VITROS assay) self-reporting 11 potential side effects. When comparing both doses respective Pfizer-BioNTech, participants receiving had higher odds many reported side-effects. same was true single-dose dose 2 vaccine. also increased each additional side-effect after second dose. ratios lower aged 65 older, females. At all timepoints, recipients ratio. Individuals fully vaccinated 72.4% compared those Moderna. Subjects asthma, diabetes, cardiovascular disease demonstrated than 20% decrease In support previous findings, we show We observed associated side-effects, history responses. This information consider further recommended.

Language: Английский

COVID-19 Risk by Workers’ Occupation and Industry in the United States, 2020‒2021 DOI
Adam Gaffney, David U. Himmelstein,

Danny McCormick

et al.

American Journal of Public Health, Journal Year: 2023, Volume and Issue: 113(6), P. 647 - 656

Published: April 13, 2023

Objectives. To assess the risk of COVID-19 by occupation and industry in United States. Methods. Using 2020-2021 National Health Interview Survey, we estimated having had a diagnosis workers' occupation, with without adjustment for confounders. We also examined period prevalence number workers household. Results. Relative to other industries occupations, those "health care social assistance" (adjusted ratio = 1.23; 95% confidence interval 1.11, 1.37), or occupations practitioners technical," support," "protective services" elevated risks COVID-19. However, compared nonworkers, 12 21 11 23 (e.g., manufacturing, food preparation, sales) were at risk. rose each additional worker Conclusions. Workers several public-facing roles adults households multiple Public Implications. Stronger workplace protections, paid sick leave, better health access might mitigate working families' from this future pandemics. (Am J Health. 2023;113(6):647-656. https://doi.org/10.2105/AJPH.2023.307249).

Language: Английский

Citations

20
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system DOI Open Access

Tyler C. Chervo,

Eric P. Elkin,

Joshua R. Nugent

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 2, 2024

Abstract Background Understanding the relative contributions of SARS-CoV-2 infection-induced and vaccine- induced seroprevalence is key to measuring overall population-level help guide policy decisions. Methods Using a series six population-based cross-sectional surveys conducted among persons aged ≥7 years in large health system with over 4.5 million members between May 2021 April 2022, we combined data from electronic record (EHR), an survey spike antibody binding assay, assess infection vaccination population- level seroprevalence. EHR were incorporated determine positivity due COVID-19 vaccination. We used sampling non-response weighting create estimates. Results enrolled 4,319 recruitment waves. increased 83.3% (CI 77.0-88.9) 93.5% 89.5-97.5) 2022. By 68.5% 61.9-74.3) population was seropositive only, 13.9% (10.7-17.9) prior diagnosed infection, 8.2% 4.5- 14.5) only 2.9% 1.1-7.6) undiagnosed only. found high agreement (≥97%) for ascertaining status. Conclusions had detectable antibody, predominantly In this highly vaccinated 18 months into pandemic, without small contributor Article summary >93% people antibodies as main driver our healthcare system. made contribution

Language: Английский

Citations

0
Organophosphate Pesticide Exposure And Risk Of Sars-Cov-2 Infection DOI
Luis López,

Katherine Kogut,

Stephen Rauch

et al.

Published: Jan. 1, 2024

Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI

Language: Английский

Citations

0
ORGANOPHOSPHATE PESTICIDE EXPOSURE AND RISK OF SARS-CoV-2 INFECTION DOI Creative Commons
Luis López, Katherine Kogut, Stephen Rauch

et al.

Environmental Research, Journal Year: 2024, Volume and Issue: 255, P. 119214 - 119214

Published: May 23, 2024

Several studies have reported immune modulation by organophosphate (OP) pesticides, but the relationship between OP exposure and SARS-CoV-2 infection is yet to be studied. We used two different measures of pesticide (urinary biomarkers (N = 154) residential proximity applications 292)) examine association early-childhood lifetime OPs risk using antibody data. Our study population consisted young adults (ages 18-21 years) from Center for Health Assessment Mothers Children Salinas (CHAMACOS) Study, a longitudinal cohort families California agricultural region. Urinary reflected in utero age 5 years. Residential exposures 16 antibodies blood samples collected June 2022 January 2023 were detected via enzyme linked immunosorbent assays, each designed bind antigens. performed logistic regression measure exposure, adjusting covariates demographic data self-reported questionnaire found increased odds among participants with higher urinary (OR 1.94, 95% CI: 0.71, 5,58) 0-5 1.90, 0.54, 6.95).

Language: Английский

Citations

0
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system DOI Creative Commons

Tyler C. Chervo,

Eric P. Elkin,

Joshua R. Nugent

et al.

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(6), P. e0303303 - e0303303

Published: June 20, 2024

Background Understanding the relative contributions of SARS-CoV-2 infection-induced and vaccine-induced seroprevalence is key to measuring overall population-level help guide policy decisions. Methods Using a series six population-based cross-sectional surveys conducted among persons aged ≥7 years in large health system with over 4.5 million members between May 2021 April 2022, we combined data from electronic record (EHR), an survey spike antibody binding assay, assess infection vaccination seroprevalence. EHR were incorporated determine positivity due COVID-19 vaccination. We used sampling non-response weighting create estimates. Results enrolled 4,319 recruitment waves. increased 83.3% (CI 77.0–88.9) 93.5% 89.5–97.5) 2022. By 68.5% 61.9–74.3) population was seropositive only, 13.9% (10.7–17.9) prior diagnosed infection, 8.2% 4.5–14.5) only 2.9% 1.1–7.6) undiagnosed only. found high agreement (≥97%) for ascertaining status. Conclusions had detectable antibody, predominantly In this highly vaccinated 18 months into pandemic, without small contributor

Language: Английский

Citations

0
Development and Implementation of Dried Blood Spot-based COVID-19 Serological Assays for Epidemiologic Studies DOI Creative Commons
Marcus P. Wong,

Michelle Meas,

Cameron Adams

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2021, Volume and Issue: unknown

Published: Nov. 28, 2021

Abstract Serological surveillance studies of infectious diseases provide population-level estimates infection and antibody prevalence, generating crucial insight into immunity, risk factors leading to infection, effectiveness public health measures. These traditionally rely on detection pathogen-specific antibodies in samples derived from venipuncture, an expensive logistically challenging aspect serological surveillance. During the COVID-19 pandemic, guidelines implemented prevent spread SARS-CoV-2 made collection venous blood difficult at a time when serosurveillance was urgently needed. Dried spots (DBS) have generated interest as alternative for applications due their stability, low cost, ease collection; DBS can be self-generated via fingerprick by community members mailed ambient temperatures. Here, we detail development four DBS-based methods demonstrate implementation large survey 12 cities East Bay region San Francisco metropolitan area using at- home collection. We find that perform similarly plasma/serum enzyme-linked immunosorbent assays commercial assays. In addition, show reliably detect responses months post-infection track kinetics after vaccination. Implementation enabled valuable data our study population investigate changes seroprevalence over eight-month period. Our work makes strong argument studies, not just SARS-CoV-2, but any situation where phlebotomy is inaccessible.

Language: Английский

Citations

1
COVID-19 vaccine antibody response is associated with side-effects, chronic health conditions, and vaccine type in a large Northern California cohort DOI Creative Commons
Olivia Solomon, Cameron Adams, Mary Horton

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Oct. 1, 2022

Abstract As vaccines have become available for COVID-19, it is important to understand factors that may impact response. The objective of this study describe vaccine response in a well-characterized Northern California cohort, including differences side-effects and antibody by type, sex, age, as well responses subjects with pre-existing health conditions are known risk more severe COVID-19 infection. From July 2020 March 2021, ∼5,500 adults from the East Bay Area were followed part longitudinal cohort study. Comprehensive questionnaire data biospecimens testing collected at multiple time-points. All least 18 years age members East-Bay who answered questionnaires related vaccination status two Three vaccines, Moderna (2 doses), Pfizer-BioNTech Johnson & (single dose), examined exposures. Additionally, assessed. main outcomes interest anti-SARS-CoV-2 Spike (measured S/C ratio Ortho VITROS assay) self-reporting 11 potential side effects. When comparing both doses respective Pfizer-BioNTech, participants receiving had higher odds many reported side-effects. same was true single-dose dose 2 vaccine. also increased each additional side-effect after second dose. ratios lower aged 65 older, females. At all timepoints, recipients ratio. Individuals fully vaccinated 72.4% compared those Moderna. Subjects asthma, diabetes, cardiovascular disease demonstrated than 20% decrease In support previous findings, we show We observed associated side-effects, history responses. This information consider further recommended.

Language: Английский

Citations

0